Form 8-K - Current report:
SEC Accession No. 0000950170-25-044375
Filing Date
2025-03-25
Accepted
2025-03-25 16:10:12
Documents
5
Period of Report
2025-03-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form-8-k-ye-2024v2.htm 8-K 48973
2 EX-99.1 tennx-ex99_1.htm EX-99.1 31675
3 GRAPHIC img152374366_0.jpg GRAPHIC 87390
4 GRAPHIC img152374366_1.jpg GRAPHIC 268098
5 GRAPHIC img152374366_2.jpg GRAPHIC 289875
  Complete submission text file 0000950170-25-044375.txt   971092
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 25768380
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)